Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

Literature DB >> 28567396

AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

Terry L Ng¹, D Ross Camidge¹.

Abstract

Entities: Disease Gene

Year: 2017 PMID： 28567396 PMCID： PMC5440295 DOI： 10.21037/atm.2017.03.73

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

24 in total

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316

2. Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?

Authors: Robert C Doebele
Journal: Nat Rev Clin Oncol Date: 2013-07-23 Impact factor: 66.675

3. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors: Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal: Lancet Oncol Date: 2015-07-06 Impact factor: 41.316

4. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors: Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal: Sci Transl Med Date: 2011-07-06 Impact factor: 17.956

5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors: Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal: N Engl J Med Date: 2010-06-24 Impact factor: 91.245

6. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

Authors: Y-L Wu; C Zhou; C-K Liam; G Wu; X Liu; Z Zhong; S Lu; Y Cheng; B Han; L Chen; C Huang; S Qin; Y Zhu; H Pan; H Liang; E Li; G Jiang; S H How; M C L Fernando; Y Zhang; F Xia; Y Zuo
Journal: Ann Oncol Date: 2015-06-23 Impact factor: 32.976

7. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors: Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal: Clin Cancer Res Date: 2013-03-07 Impact factor: 12.531

8. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544

9. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

10. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Authors: Glenwood Goss; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Jong Seok Lee; Gee-Chen Chang; Lucio Crino; Miyako Satouchi; Quincy Chu; Toyoaki Hida; Ji-Youn Han; Oscar Juan; Frank Dunphy; Makoto Nishio; Jin-Hyoung Kang; Margarita Majem; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Tetsuya Mitsudomi
Journal: Lancet Oncol Date: 2016-10-14 Impact factor: 41.316

1 in total

1. Diagnosis and treatment of non-small cell lung cancer: current advances and challenges.

Authors: Ian Diebels; Paul E Y Van Schil
Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005

1 in total